KEVIN TANG
CIK 1178579 · Chief Executive Officer · last filed 2026-08-28
KEVIN TANG is a Chief Executive Officer who has filed 78 SEC Form 4 insider transactions across 13 companies since 2008. The most recent filing shows the insider sold $108.7K of BOLD on Aug 28, 2026. Across all open-market trades the lifetime net is +$167.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $221.4M across reported positions. 217 SEC filings were submitted jointly with TANG CAPITAL MANAGEMENT LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$221.45M
13
78
$167.23M
Filer Profile
SUITE 210
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOLD | 10%+ Owner | 2,840,635 | $2.83 | $8.04M | -$108.7K | 1 | 2026-08-28 |
| AUPH | Director | 12,229,500 | $16.10 | $196.89M | $49.81M | 4 | 2026-03-03 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 4,338,617 | $1.48 | $6.42M | $262.9K | 1 | 2023-05-15 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 10,000 | $1.88 | $18.8K | $0 | 1 | 2023-05-05 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Director | 10,049,224 | $6.22 | $62.51M | $108.22M | 16 | 2022-01-14 |
| Odonate Therapeutics, Inc. (ODT) Delisted | Chief Executive Officer | 15,375,428 | $1.12 | $17.22M | $181.59M | 13 | 2020-12-23 |
| HRTX | Director | 5,806,751 | $0.32 | $1.83M | -$194.04M | 10 | 2019-12-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 0 | — | — | $21.77M | 8 | 2012-06-20 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2010-09-22 |
| VNDA | 10%+ Owner | 2,884,671 | $5.09 | $14.68M | -$3.12M | 3 | 2010-01-13 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | 10%+ Owner | 16,496 | — | — | $1.82M | 2 | 2008-12-22 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 13,500 | — | — | $18.0K | 1 | 2008-10-15 |
| NEOSE TECHNOLOGIES INC (NTEC) Delisted | 10%+ Owner | 487,506 | $9.63 | $4.69M | $995.6K | 1 | 2008-09-22 |
Recent Filings
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-28 | BOLD | Sell (S) | −36,600 | -$108.7K | EDGAR |
| 2026-03-03 | AUPH | Buy (P) | +900,000 | $12.69M | EDGAR |
| 2025-08-05 | AUPH | Buy (P) | +1,300,000 | $13.59M | EDGAR |
| 2025-03-04 | AUPH | Buy (P) | +1,600,000 | $12.71M | EDGAR |
| 2024-12-09 | AUPH | Buy (P) | +1,200,000 | $10.82M | EDGAR |
| 2023-05-15 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Buy (P) | +134,844 | $262.9K | EDGAR |
| 2023-05-05 | Jounce Therapeutics, Inc. (JNCE) Delisted | Mixed | −15,870,261 | $262.72M | EDGAR |
| 2022-08-24 | — | U | −38,431,736 | -$239.43M | |
| 2022-08-24 | — | Mixed | −9,607,934 | -$59.86M | |
| 2022-01-14 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.